CEACAM5 and lung adenocarcinoma: Our study suggests that CA-199 has a better ability to predict PFS than CEA in patients with stage IV lung adenocarcinoma; however, the opposite was true for early-stage patients, where CA-199 could not predict PFS, while CEA could.